(S (NP (NN Immunogenicity)) (VP (VBZ is) (NP (NP (DT a) (JJ major) (NN problem)) (PP (IN during) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNS biotherapeutics)))))) (SBAR (IN since) (S (NP (PRP it)) (VP (MD can) (VP (VB lead) (PP (IN to) (NP (NP (JJ rapid) (NN clearance)) (PP (IN of) (NP (NP (DT the) (NN drug)) (CC and) (NP (JJ adverse) (NNS reactions))))))))))) (. .))
(S (NP (NP (DT The) (NN challenge)) (PP (IN for) (NP (JJ biotherapeutic) (NN design)))) (VP (VBZ is) (ADVP (RB therefore)) (S (VP (TO to) (VP (VB identify) (NP (NP (NNS mutants)) (PP (IN of) (NP (NP (DT the) (NN protein) (NN sequence)) (SBAR (WHNP (WDT that)) (S (VP (VBP minimize) (NP (NP (NN immunogenicity)) (PP (IN in) (NP (DT a) (NN target) (NN population)))) (PP (IN whilst) (S (VP (VBG retaining) (NP (JJ pharmaceutical) (NML (NN activity) (CC and) (NN protein)) (NN function))))))))))))))) (. .))
(S (S (NP (JJ Current) (NNS approaches)) (VP (VP (VBP are) (ADJP (RB moderately) (JJ successful) (PP (IN in) (S (VP (VBG designing) (NP (NNS sequences)) (PP (IN with) (NP (VBN reduced) (NN immunogenicity)))))))) (, ,) (CC but) (VP (VBP do) (RB not) (VP (VB account) (PP (IN for) (NP (NP (DT the) (VBG varying) (NNS frequencies)) (PP (IN of) (NP (NP (JJ different) (NML (JJ human) (NN leucocyte) (NN antigen)) (NNS alleles)) (PP (IN in) (NP (DT a) (JJ specific) (NN population))))))))))) (CC and) (S (PP (IN in) (NP (NN addition))) (, ,) (SBAR (IN since) (S (NP (JJ many) (NNS designs)) (VP (VBP are) (ADJP (JJ non-functional))))) (, ,) (VP (VBP require) (ADJP (JJ costly) (JJ experimental) (JJ post-screening)))) (. .))
(S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP report) (NP (NP (DT a) (JJ new) (NN method)) (PP (IN for) (NP (NN de-immunization) (NN design)))) (S (VP (VBG using) (NP (NP (JJ multi-objective) (JJ combinatorial) (NN optimization)) (SBAR (WHNP (WDT that)) (S (ADVP (RB simultaneously)) (VP (VBZ optimizes) (NP (NP (DT the) (NN likelihood)) (PP (IN of) (NP (NP (DT a) (JJ functional) (NN protein) (NN sequence)) (PP (IN at) (NP (DT the) (JJ same) (NN time)))))) (PP (IN as) (S (VP (VBG minimizing) (NP (NP (PRP$ its) (NN immunogenicity)) (VP (VBN tailored) (PP (IN to) (NP (DT a) (NN target) (NN population))))))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP bypass) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (ADJP (CD three) (HYPH -) (JJ dimensional)) (NN protein) (NN structure)) (CC or) (NP (JJ molecular) (NNS simulations))))) (S (VP (TO to) (VP (VB identify) (NP (JJ functional) (NNS designs)) (PP (IN by) (S (ADVP (RB automatically)) (VP (VBG generating) (NP (NNS sequences)) (S (VP (VBG using) (NP (NP (JJ probabilistic) (NNS models)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN been) (VP (VBN used) (ADVP (RB previously)) (PP (IN for) (NP (NP (NN mutation) (NN effect) (NN prediction)) (CC and) (NP (NN structure) (NN prediction))))))))))))))))))) (. .))
(S (PP (IN As) (NP (NN proof) (HYPH -) (IN of) (HYPH -) (NN principle))) (NP (PRP we)) (VP (VP (VBD designed) (NP (NP (NNS sequences)) (PP (IN of) (NP (NP (DT the) (NN C2) (NN domain)) (PP (IN of) (NP (NN Factor) (CD VIII))))))) (CC and) (VP (VBD tested) (NP (PRP them)) (ADVP (RB experimentally)) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (DT a) (JJ good) (NN correlation))) (PP (IN with) (NP (NP (DT the) (VBN predicted) (NN immunogenicity)) (PP (IN of) (NP (PRP$ our) (NN model))))))))) (. .))
